



NDA 50420/S-076
NDA 50627/S-017

SUPPLEMENT APPROVAL

sanofi-aventis U.S. LLC., A SANOFI COMPANY
Attention: John Cook
Director, U.S. Regulatory Affairs Marketed Products
55 Corporate Drive, Mailstop 55C-205A
Bridgewater, NJ 08807

Dear Mr. Cook:

Please refer to your Supplemental New Drug Applications (sNDAs) dated October 24, 2016, received October 24, 2016, and your amendments dated April 14, 2017, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for RIFADIN (rifampin) capsules USP [NDA 50-420] and RIFADIN IV (rifampin for injection) USP [NDA 50-627].

These “Changes Being Effected” supplemental new drug applications provide for revisions to the **WARNINGS**, **PRECAUTIONS** and **ADVERSE REACTIONS** sections of the package insert(s) as follows:

WARNINGS

Revised to include Drug Reaction Eosinophilia and Systemic Symptoms syndrome (DRESS) and to update signs and symptoms of drug-induced hypersensitivity reactions.

PRECAUTIONS

The **Information for Patients** subsection has been revised to include more descriptive information for patients related to hypersensitivity reactions and rash.

ADVERSE REACTIONS

The **Hypersensitivity Reactions** subsection has been revised to add Drug Reaction with Eosinophilia and Systemic Symptoms syndrome (DRESS).

Additionally, minor editorial revisions have been made throughout the package insert.

APPROVAL & LABELING

We have completed our review of these supplemental applications, as amended. They are approved, effective on the date of this letter, for use as recommended in the enclosed, agreed-upon labeling text.

CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at <http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm>. Content of labeling must be identical to the enclosed labeling (text for the package insert), with the addition of any labeling changes in pending “Changes Being Effectuated” (CBE) supplements, as well as annual reportable changes not included in the enclosed labeling.

Information on submitting SPL files using eList may be found in the guidance for industry titled “SPL Standard for Content of Labeling Technical Qs and As at <http://www.fda.gov/downloads/DrugsGuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf>

The SPL will be accessible from publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications that include labeling changes for this NDA, including CBE supplements for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(l)(1)(i)] in MS Word format, that includes the changes approved in this supplemental application, as well as annual reportable changes and annotate each change. To facilitate review of your submission, provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

REPORTING REQUIREMENTS

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Mr. Gregory DiBernardo, Regulatory Project Manager, at (301) 796-4063.

Sincerely,

{See appended electronic signature page}

Joseph G. Toerner, M.D., M.P.H.
Deputy Director for Safety
Division of Anti-Infective Products
Office of Antimicrobial Products
Center for Drug Evaluation and Research

ENCLOSURE:
Content of Labeling

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

JOSEPH G TOERNER
04/24/2017